Allergan : New Study Showcases Economic Impact of Allergan Operations on French Economy

PARIS, FRANCE - SEPTEMBER 25, 2017 - A new study conducted by Asterès, a Paris-based economic consulting firm, finds biopharmaceutical company Allergan's operations in France contributed €326 million to the country's economy in 2016. The report also found that Allergan generates in a direct, indirect and induced manner, a total annual impact of approximately €160 million for French businesses, and produced added value of €261 million to the French economy in 2016.

The contribution is primarily a result of Allergan's significant investment in its manufacturing and research and development facilities in France, as well as its substantial employment base in the country.

'Allergan epitomizes the importance of biopharmaceutical companies to the French economy, employing more than 500 people and achieving sales that topped €500 million in 2016,' said Asterès Economist Christophe Marques, who conducted the study. 'Allergan's investments, purchases and compensation to employees generate a ripple effect on the rest of the French economy. The impact is significant.'

Additional findings from the Asterès study included:

• Allergan directly employs 511 people in France. Including suppliers and service providers, Allergan supports an estimated total of 1,200 jobs in France.
• Allergan created 170 direct jobs in France between 2008 and June 2017, increasing its French employment by 50 percent during a period when France's overall industrial employment declined.
• Allergan's €43.6 million in employee compensation in 2016 includes wages, salaries and social contributions. Allergan employees contributed an estimated €16.5 million in domestic consumption in 2016, supporting France's businesses and economy.
• Allergan paid €69 million in taxes to France in 2016 and €293 million in taxes between 2012-2016.
• Allergan invested €100 million in France between 2007 and 2016, primarily on its manufacturing and research and development facility in Pringy.

'Allergan's colleagues in France play a critical role in supporting research, manufacturing and distribution of our medicines for patients around the globe. And our commercial colleagues have made France a top market for Allergan internationally. I thank them for their many contributions to our Company, and applaud them for their significant role in supporting France's economy and Allergan's global success,' said Brent Saunders, Chairman and CEO of Allergan.

'Allergan has had a strong business in France for nearly 40 years, allowing us to greatly expand our operations and create jobs. We are proud of our economic impact in France, supporting not only our colleagues, but also hundreds of indirect employees, including suppliers. We thank our customers in France who have been essential to Allergan's success in helping patients live healthier, happier lives. We look forward to expanding our partnership with France and to making significant contributions to the French economy for many years to come,' said Pascal Brice, General Manager for Allergan's manufacturing and research and development site in Pringy, France.

The study, titled 'The Economic Impact of Allergan's Operations in France' was commissioned by Allergan to mark the upcoming 40th anniversary of its operations in France. Full-text of the original report and the supplement are available via the following links:

September 2017 Economic Impact Study: https://www.allergan.com/miscellaneous-pages/allergan-pdf-files/allergan-impact-on-the-french-economy-2017-report.pdf
September 2017 Economic Impact Study Supplement: https://www.allergan.com/miscellaneous-pages/allergan-pdf-files/allergan-impact-on-the-french-economy-2017-highlig.pdf

About Allergan's France Operations
Allergan employs more than 500 employees at two sites in France. These are the commercial headquarters based in Place de la Défense, Paris and the state of the art R&D and manufacturing site in Pringy, Annecy where Allergan produces the global supply of its leading JUVEDERM Collection® of fillers. Allergan France commercializes a wide portfolio of medicines and medical devices in the following therapeutic areas: medical aesthetics, ophthalmology, neuroscience, gastroenterology and urology.

About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model - Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:

Allergan:

Investors:

Daphne Karydas
(862) 261-8006

Media:

Mark Marmur
(862) 261-7558

Jean-Yves Goar
+33 686 200 168